Diagnosis and Management of Microscopic Colitis

American Journal of Gastroenterology

Volumn 112, Issue 1, 2017, Pages 78-85

  Pardi, Darrell S ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIGEN; BILE ACID; COLLAGEN; HORMONE; LUMINAL ANTIGEN; UNCLASSIFIED DRUG; ANION EXCHANGE RESIN; ANTIDIARRHEAL AGENT; BUDESONIDE; COLESTYRAMINE; GLUCOCORTICOID; HLA ANTIGEN; MESALAZINE; NONSTEROID ANTIINFLAMMATORY AGENT;

ARTICLE; AUTOIMMUNITY; CLINICAL FEATURE; COLLAGEN METABOLISM; DISEASE MANAGEMENT; DRUG THERAPY; FLUID BALANCE; GENETIC PREDISPOSITION; HOMEOSTASIS; HUMAN; INFECTION; META ANALYSIS (TOPIC); MICROSCOPIC COLITIS; PATHOPHYSIOLOGY; PHYSICAL DISEASE BY COMPOSITION OF BODY FLUIDS, EXCRETA AND SECRETIONS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); SIDE EFFECT; SYSTEMATIC REVIEW (TOPIC); COLITIS, COLLAGENOUS; COLITIS, LYMPHOCYTIC; COLITIS, MICROSCOPIC; COLON; GENETICS; IMMUNOLOGY; METABOLISM; PATHOLOGY;

ANION EXCHANGE RESINS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTIDIARRHEALS; AUTOIMMUNITY; BILE ACIDS AND SALTS; BUDESONIDE; CHOLESTYRAMINE RESIN; COLITIS, COLLAGENOUS; COLITIS, LYMPHOCYTIC; COLITIS, MICROSCOPIC; COLLAGEN; COLON; GENETIC PREDISPOSITION TO DISEASE; GLUCOCORTICOIDS; HLA ANTIGENS; HUMANS; MESALAMINE;

EID: 85000577480     PISSN: 00029270     EISSN: 15720241     Source Type: Journal    
DOI: 10.1038/ajg.2016.477     Document Type: Article

References (136)

1. Hjortswang H, Tysk C, Bohr J et al. Defining clinical criteria for clinical remission and disease activity in collagenous colitis. Inflamm Bow Dis 2009; 15: 1875-81.
2. Madisch A, Heymer P, Voss C et al. Oral budesonide therapy improves quality of life in patients with collagenous colitis. Int J Colorectal Dis 2005; 20: 312-6.
3. Nyhlin N, Wickbom A, Montgomery SM et al. Long-term prognosis of clinical symptoms and health-related quality of life in microscopic colitis: a case-control study. Aliment Pharmacol Ther 2014; 39: 963-72.
4. Madisch A, Bethke B, Stolte M et al. Is there an association of microscopic colitis and irritable bowel syndrome-a subgroup analysis of placebocontrolled trials. World J Gastroenterol 2005; 11: 6409.
5. Limsui D, Pardi DS, Camilleri M et al. Symptomatic overlap between irritable bowel syndrome and microscopic colitis. Inflamm Bowel Dis 2007; 13: 175-81.
6. Abboud R, Pardi DS, Tremaine WJ et al. Symptomatic overlap between microscopic colitis and irritable bowel syndrome: a prospective study. Inflamm Bowel Dis 2013; 19: 550-3.
7. Macaigne G, Lahmek P, Locher C et al. Microscopic colitis or functional bowel disease with diarrhea: a French prospective multicenter study. Am J Gastroenterol 2014; 109: 1461-70.
8. Kane JS, Rotimi O, Everett SM et al. Development and validation of a scoring system to identify patients with microscopic colitis. Clin Gastroenterol Hepatol 2015; 13: 1125-31.
9. Jessurun J, Yardley JH, Lee EL et al. Microscopic and collagenous colitis: different names for the same condition? Gastroenterology 1986; 91: 1583-4.
10. Kakar S, Pardi DS, Burgart LJ. Colonic ulcers accompanying collagenous colitis: implication of NSAIDs. Am J Gastroenterol 2003; 98: 1834-7.
11. Bohr J, Tysk C, Yang P et al. Autoantibodies and immunoglobulins in collagenous colitis. Gut 1996; 39: 73-6.
12. Freeman HJ. Perinuclear antineutrophil cytoplasmic antibodies in collagenous or lymphocytic colitis with or without celiac disease. Can J Gastroenterol 1997; 11: 417-20.
13. Olesen M, Eriksson S, Bohr J et al. Microscopic colitis: a common diarrhoeal disease. An epidemiological study in Orebro, Sweden, 1993-1998. Gut 2004; 53: 346-50.
14. Bohr J, Tysk C, Eriksson S et al. Collagenous colitis: a retrospective study of clinical presentation and treatment in 163 patients. Gut 1996; 39: 846-51.
15. Pardi DS, Ramnath VR, Loftus EV et al. Lymphocytic colitis: clinical features, treatment, and outcomes. Am J Gastroenterol 2002; 97: 2829-33.
16. Wolber R, Owen D, Freeman H. Colonic lymphocytosis in patients with celiac sprue. Hum Pathol 1990; 21: 1092-6.
17. Breen EG, Coughlan G, Connolly CE et al. Coeliac proctitis. Scand J Gastroenterol 1987; 22: 471-7.
18. Green PHR, Yang J, Cheng J et al. An association between microscopic colitis and celiac disease. Clin Gastroenterol Hepatol 2009; 7: 1210-6.
19. Rubio-Tapia A, Hill ID, Kelly CP et al. ACG clinical guidelines: diagnosis and management of celiac disease. Am J Gastroenterol 2013; 108: 656-76.
20. Fine KD, Do K, Schulte K et al. High prevalence of celiac sprue-like HLA-DQ genes and enteropathy in patients with the microscopic colitis syndrome. Am J Gastroenterol 2000; 95: 1974-82.
21. Giardiello FM, Jackson FW, Lazenby AJ. Metachronous occurrence of collagenous colitis and ulcerative colitis. Gut 1991; 32: 447-9.
22. Pokorny CS, Kneale KL, Henderson CJ. Progression of collagenous colitis to ulcerative colitis. J Clin Gastroenterol 2001; 32: 435-8.
23. Ayata G, Ithamukkala S, Sapp H et al. Prevalence and significance of inflammatory bowel disease-like morphological features in collagenous and lymphocytic colitis. Am J Surg Pathol 2002; 26: 1414-23.
24. Mullhaupt B, Guller U, Anabitarte M et al. Lymphocytic colitis: clinical presentation and long term course. Gut 1998; 43: 629-33.
25. Baert F, Wouters K, D'Haens G et al. Lymphocytic colitis: a distinct clinical entity? A clinicopathological confrontation of lymphocytic and collagenous colitis. Gut 1999; 45: 375-81.
26. Bonner GF, Petras RE, Cheong DMO et al. Short-and long-term followup of treatment for lymphocytic and collagenous colitis. Inflamm Bowel Dis 2000; 6: 85-91.
27. Bonderup OK, Folkersen BH, Gjersoe P, Teglbjaerg PS. Collagenous colitis: a long-term follow-up study. Eur J Gastroenterol Hepatol 1999; 11: 493-5.
28. Madisch A, Miehlke S, Lindner M et al. Clinical course of collagenous colitis over a period of 10 years. Z Gastroenterol 2006; 44: 971-4.
29. GoffJS, Barnett JL, Pelke T et al. Collagenous colitis: histopathology and clinical course. Am J Gastroenterol 1997; 92: 57-60.
30. O'Toole A, Coss A, Holleran G et al. Microscopic colitis: clinical characteristics, treatment and outcomes in an Irish population. Int J Colorectal Dis 2014; 29: 799-803.
31. Bonderup OK, Hansen JB, Birket-Smith L et al. Budesonide treatment of collagenous colitis: a randomized, double-blind, placebo controlled trial with morphometric analysis. Gut 2003; 52: 248-51.
32. Baert F, Schmit A, D'Haens G et al. Budesonide in collagenous colitis: a double-blind placebo-controlled trial with histologic follow-up. Gastroenterology 2002; 122: 20-25.
33. Miehlke S, Heymer P, Bethke B et al. Budesonide treatment for collagenous colitis: a randomized, double-blind, placebo-controlled, multicenter trial. Gastroenterology 2002; 123: 978-84.
34. Miehlke S, Madish A, Karimi D et al. A randomized double-blind, placebo-controlled study showing that budesonide is effective in treating lymphocytic colitis. Gastroenterology 2009; 136: 2092-100.
35. Pardi DS, Loftus EV, Tremaine WJ et al. A randomized, double-blind, placebo-controlled trial of budesonide for the treatment of active lymphocytic colitis. Gastroenterology 2009; 136: A519.
36. Gentile NM, Abdalla AA, Khanna S et al. Outcomes of patients with microscopic colitis treated with corticosteroids: a population-based study. Am J Gastroenterol 2013; 108: 256-9.
37. Bohr J, Tysk C, Eriksson S et al. Collagenous colitis in Orebro, Sweden, an epidemiological study 1984-1993. Gut 1995; 37: 394-7.
38. Fernandez-Banares F, Salas A, Forne M et al. Incidence of collagenous and lymphocytic colitis: a 5-year population-based study. Am J Gastroenterol 1999; 94: 418-23.
39. Olesen M, Eriksson S, Bohr J et al. Lymphocytic colitis: a retrospective clinical study of 199 Swedish patients. Gut 2004; 53: 536-41.
40. Agnarsdottir M, Gunnlaugsson O, Orvar KB et al. Collagenous and lymphocytic colitis in Iceland. Dig Dis Sci 2002; 47: 1122-8.
41. Williams JJ, Kaplan GG, Makhija S et al. Microscopic colitis-defining incidence rates and risk factors: a population-based study. Clin Gastroenterol Hepatol 2008; 6: 35-40.
42. Gremse DA, Boudreaux CW, Manci EA. Collagenous colitis in children. Gastroenterology 1993; 104: 906-9.
43. Narla NP, Smyrk TC, Pardi DS et al. Clinical features and treatment responses in pediatric lymphocytic and collagenous colitis. J Pediatr Gastroenterol Nutr 2013; 57: 557-61.
44. Tontini GE, Pastorelli L, Spina L et al. Microscopic colitis and colorectal neoplastic lesion rate in chronic nonbloody diarrhea: a prospective, multicenter study. Inflamm Bowel Dis 2014; 20: 882-91.
45. Genta RM, Sonnenberg A. The yield of colonic biopsy in the evaluation of chronic unexplained diarrhea. Eur J Gastroenterol Hepatol 2015; 27: 963-7.
46. Pardi DS, Loftus EV, Smyrk TC et al. The epidemiology of microscopic colitis: a population based study in Olmsted County, Minnesota. Gut 2007; 56: 504-8.
47. Gentile NM, Khanna S, Loftus EV Jr et al. The epidemiology of microscopic colitis in Olmsted County from 2002 to 2010: a population-based study. Clin Gastroenterol Hepatol 2014; 12: 838-42.
48. Verhaegh BP, Jonkers DM, Driessen A et al. Incidence of microscopic colitis in the Netherlands. A nationwide population-based study from 2000 to 2012. Dig Liver Dis 2015; 47: 30-6.
49. Bonderup OK, Wigh T, Nielsen GL et al. The epidemiology of microscopic colitis: a 10-year pathology-based nationwide Danish cohort study. Scand J Gastroenterol 2015; 50: 393-8.
50. Tong J, Zheng Q, Zhang C et al. Incidence, prevalence, and temporal trends of microscopic colitis: a systematic review and meta-analysis. Am J Gastroenterol 2015; 110: 265-76.
51. Wickbom A, Bohr J, Eriksson S et al. Stable incidence of collagenous colitis and lymphocytic colitis in Orebro, Sweden, 1999-2008: a continuous epidemiologic study. Inflamm Bowel Dis 2013; 19: 2387-93.
52. Masclee GM, Coloma PM, Kuipers EJ et al. Incidence of microscopic colitis in relation to the number of colonoscopies. Am J Gastroenterol 2015; 110: 1246-7.
53. Sonnenberg A, Turner KO, Genta RM. Differences in the socio-economic distribution of inflammatory bowel disease and microscopic colitis. Colorectal Dis 2016 (epub ahead of print).
54. Turner K, Genta RM, Sonnenberg A. Ethnic distribution of microscopic colitis in the United States. Inflamm Bowel Dis 2015; 21: 2634-9.
55. Chan JL, Tersmette AC, Offerhaus GJ et al. Cancer risk in collagenous colitis. Inflamm Bowel Dis 1999; 5: 40-3.
56. Yen EF, Pokhrel B, Bianchi LK et al. Decreased colorectal cancer and adenoma risk in patients with microscopic colitis. Dig Dis Sci 2012; 57: 161-9.
57. Sonnenberg A, Genta RM. Low prevalence of colon polyps in chronic inflammatory conditions of the colon. Am J Gastroenterol 2015; 110: 1056-61.
58. Fernandez-Banares F, de Sousa MR, Salas A et al. Epidemiological risk factors in microscopic colitis: a prospective case-control study. Inflamm Bowel Dis 2013; 19: 411-7.
59. Fernandez-Banares F, de Sousa MR, Salas A et al. Impact of current smoking on the clinical course of microscopic colitis. Inflamm Bowel Dis 2013; 19: 1470-6.
60. Dobbins W, Rubin C. Studies of the rectal mucosa and celiac sprue. Gastroenterology 1964; 47: 471-9.
61. Jarnerot G, Tysk C, Bohr J et al. Collagenous colitis and fecal stream diversion. Gastroenterology 1995; 109: 449-55.
62. Larsson JK, Sonestedt E, Ohlsson B et al. The association between the intake of specific dietary components and lifestyle factors and microscopic colitis. Eur J Clin Nutr 2016; 70: 1309-17.
63. Fischer H, Holst E, Karlsson F et al. Altered microbiota in microscopic colitis. Gut 2015; 64: 1185-6.
64. Sonnenberg A, Genta RM. Inverse association between helicobacter pylori gastritis and microscopic colitis. Inflamm Bowel Dis 2016; 22: 182-6.
65. Sylwestrowicz T, Kelly JK, Hwang WS et al. Collagenous colitis and microscopic colitis: the watery diarrhea-colitis syndrome. Am J Gastroenterol 1989; 84: 763-8.
66. Giardiello FM, Lazenby AJ, Bayless TM et al. Lymphocytic (microscopic) colitis. Clinicopathologic study of 18 patients and comparison to collagenous colitis. Dig Dis Sci 1989; 34: 1730-8.
67. Sikander A, Sinha SK, Prasad KK et al. Association of serotonin transporter promoter polymorphism (5-HTTLPR) with microscopic colitis and ulcerative colitis. Dig Dis Sci 2015; 60: 887-94.
68. Roda G, Torres J, Hu J et al. Genome-wide association identifies multiple collagenous colitis susceptibility loci. Gastroenterology 2015; 148: S-875.
69. Jarnerot G, Hertervig E, Granno C et al. Familial occurrence of microscopic colitis: a report on five families. Scand J Gastroenterol 2001; 36: 959-62.
70. Roth B, Manjer J, Ohlsson B. Microscopic colitis and reproductive factors related to exposure to estrogens and progesterone. Drug Target Insights 2013; 7: 53-62.
71. Burgel N, Bojarski C, Mankertz J et al. Mechanisms of diarrhea in collagenous colitis. Gastroenterology 2002; 123: 433-43.
72. Giardiello FM, Bayless TM, Jessurun J et al. Collagenous colitis: physiologic and histopathologic studies in seven patients. Ann Intern Med 1987; 106: 46-9.
73. Rask-Madsen J, Grove O, Hansen MGJ et al. Colonic transport of water and electrolytes in a patient with secretory diarrhea due to collagenous colitis. Dig Dis Sci 1983; 28: 1141-6.
74. Loo FD, Wood CM, Soergel KH et al. Abnormal collagen deposition and ion transport in collagenous colitis. Gastroenterology 1985; 88: 1481.
75. Kingham JGC, Levison DA, Ball JA et al. Microscopic colitis-a cause of chronic watery diarrhea. Br Med J 1992; 285: 1601-4.
76. Lundberg JO, Herulf M, Olesen M et al. Increased nitric oxide production in collagenous and lymphocytic colitis. Eur J Clin Invest 1997; 27: 869-71.
77. Chadwick VS, Gaginella TS, Carlson GL et al. Effect of molecular structure on bile acid induced alterations in absorptive function, permeability and morphology in the perfused rabbit colon. J Lab Clin Med 1979; 94: 661-74.
78. Breuer NF, Rampton DS, Tammar A et al. Effect of colonic perfusion with sulfated and nonsulfated bile acids on mucosal structure and function in the rat. Gastroenterology 1983; 84: 969-77.
79. Einarsson K, Eusufzai S, Johansson U et al. Villous atrophy of distal ileum and lymphocytic colitis in a woman with bile acid malabsorption. Eur J Gastroenterol Hepatol 1992; 4: 585-90.
80. Lewis FW, Warren GH, GoffJS. Collagenous colitis with involvement of terminal ileum. Dig Dis Sci 1991; 36: 1161-3.
81. Marteau P, Lavergne-Slove A, Lemann M et al. Primary villous atrophy is often associated with microscopic colitis. Gut 1997; 41: 561-4.
82. Fernandez-Banares F, Esteve M, Salas A et al. Bile acid malabsorption in microscopic colitis and in previously unexplained functional chronic diarrhea. Dig Dis Sci 2001; 46: 2231-8.
83. Eusufzai S, Lofb erg R, Veress B et al. Studies on bile acid metabolism in collagenous colitis: no evidence of bile acid malabsorption as determined by the SeHCATtest. Eur J Gastroenterol Hepatol 1992; 4: 317-21.
84. Ung KA, Gillberg R, Kilander A et al. Role of bile acids and bile acid binding agents in patients with collagenous colitis. Gut 2000; 46: 170-5.
85. Osterholm MT, MacDonald KL, White KE et al. An outbreak of a newly recognized chronic diarrhea syndrome associated with raw milk consumption. JAMA 1986; 256: 484-90.
86. Riddell RH, Tanaka M, Mazzoleni G. Non-steroidal anti-inflammatory drugs as a possible cause of collagenous colitis: a case-control study. Gut 1992; 33: 683-6.
87. Giardiello FM, Hansen FC, Lazenby AJ et al. Collagenous colitis in setting of nonsteroidal antiinflammatory drugs and antibiotics. Dig Dis Sci 1990; 35: 257-60.
88. Masclee GM, Coloma PM, Kuipers EJ et al. Increased risk of microscopic colitis with use of proton pump inhibitors and non-steroidal anti-inflammatory drugs. Am J Gastroenterol 2015; 110: 749-59.
89. Bonderup OK, Fenger-Gron M, Wigh T et al. Drug exposure and risk of microscopic colitis: a nationwide Danish case-control study with 5751 cases. Inflamm Bowel Dis 2014; 20: 1702-7.
90. Fernandez-Banares F, Esteve M, Espinos JC et al. Drug consumption and the risk of microscopic colitis. Am J Gastroenterol 2007; 102: 324-30.
91. Verhaegh BP, de Vries F, Masclee AA et al. High risk of drug-induced microscopic colitis with concomitant use of NSAIDs and proton pump inhibitors. Aliment Pharmacol Ther 2016; 43: 1004-13.
92. Beaugerie L, Pardi DS. Review article: drug-induced microscopic colitis- proposal for a scoring system and review of the literature. Aliment Pharmacol Ther 2005; 22: 277-84.
93. Aigner T, Neureiter D, Muller S et al. Extracellular matrix composition and gene expression in collagenous colitis. Gastroenterology 1997; 113: 136-43.
94. Gunther U, Schuppan D, Bauer M et al. Fibrogenesis and fibrolysis in collagenous colitis. Am J Pathol 1999; 155: 493-503.
95. StampflDA, Friedman LS. Collagenous colitis. Pathophysiologic considerations. Dig Dis Sci 1991; 36: 705-11.
96. Stahle-Backdahl M, Maim J, Veress B et al. Increased presence of eosinophilic granulocytes expressing transforming growth factor-beta1 in collagenous colitis. Scand J Gastroenterol 2000; 35: 742-6.
97. Griga T, Tromm A, Schmiegel W et al. Collagenous colitis: implications for the role of vascular endothelial growth factor in repair mechanisms. Eur J Gastroenterol Hepatol 2004; 16: 397-402.
98. Taha Y, Raab Y, Larsson A et al. Vascular endothelial growth factor (VEGF)-a possible mediator of inflammation and mucosal permeability in patients with collagenous colitis. Dig Dis Sci 2004; 49: 109-15.
99. Taha Y, Raab Y, Larsson A et al. Mucosal secretion and expression of basic fibroblast growth factor in patients with collagenous colitis. Am J Gastroenterol 2003; 98: 2011-7.
100. Hwang WS, Kelly JK. Collagenous colitis: a disease of pericryptal fibroblast sheath? J Pathol 1986; 149: 33-40.
101. Lee E, Schiller LR, Vendrell D et al. Subepithelial collagen table thickness in colon specimens from patients with microscopic colitis and collagenous colitis. Gastroenterology 1992; 103: 1790-6.
102. von Arnim U, Wex T, Ganzert C et al. Fecal calprotectin: a marker for clinical differentiation of microscopic colitis and irritable bowel syndrome. Clin Exp Gastroenterol 2016; 9: 97-103.
103. Wagner M, Sjoberg K, Vigren L et al. Elevated fecal levels of eosinophil granule proteins predict collagenous colitis in patients referred to colonoscopy due to chronic non-bloody diarrhea. Scand J Gastroenterol. 2016 51: 835-41.
104. Carpenter HA, Tremaine WJ, Batts KP et al. Sequential histologic evaluations in collagenous colitis. Correlations with disease behavior and sampling strategy. Dig Dis Sci 1992; 37: 1903-9.
105. Thijs WJ, van Baarlen J, Kleibeuker JH et al. Microscopic colitis: prevalence and distribution throughout the colon in patients with chronic diarrhoea. Neth J Med 2005; 63: 137-40.
106. Tanaka M, Mazzoleni G, Riddell RH. Distribution of collagenous colitis: utility of flexible sigmoidoscopy. Gut 1992; 33: 65-70.
107. Matteoni CA, Wang N, Goldblum JR et al. Flexible sigmoidoscopy for the detection of microscopic colitis. Am J Med 2000; 108: 416-8.
108. Yen EF, Hall CR, Witt B. Yield of sigmoid and rectal biopsies in the detection of microscopic colitis. Gastroenterology 2010; 138: S638.
109. Rasmussen J, Engel PJ, Wildt S et al. The temporal evolution of histologic abnormalities in microscopic colitis. J Crohns Colitis 2016; 10: 262-8.
110. Kane JS, Bryan H, Ford AC. Reducing the need for random colonic biopsies in patients with diarrhea. Am J Gastroenterol 2015; 110: 351-2.
111. Cotter TG, Binder M, Pardi DS. Validation of a scoring system to predict microscopic colitis in a cohort of patients with chronic diarrhea. Clin Gastroenterol Hepatol 2016; 14: 777-8.
112. Kane JS, Sood R, Law GR et al. Validation and modification of a diagnostic scoring system to predict microscopic colitis. Scand J Gastroenterol 2016; 51: 1206-12.
113. Cotter TG, Binder M, Harper EP et al. Optimization of a scoring system to predict microscopic colitis in a cohort of patients with chronic diarrhea. J Clin Gastroenterol 2016 (epub ahead of print).
114. Fine KD, Lee EL. Efficacy of open-label bismuth subsalicylate for the treatment of microscopic colitis. Gastroenterology 1998; 114: 29-36.
115. Gentile NM, Khanna S, Loftus EV et al. Outcomes of patients with microscopic colitis treated with bismuth subsalicylate. Gastroenterology 2015; 148: S-483.
116. Colussi D, Salari B, Stewart KO et al. Clinical characteristics and patterns and predictors of response to therapy in collagenous and lymphocytic colitis. Scand J Gastroenterol 2015; 21: 1-7.
117. Masannat Y, Nazer E. Pepto bismuth associated neurotoxicity: a rare side effect of a commonly used medication. W V Med J 2013; 109: 32-4.
118. Miehlke S, Madisch A, Kupcinskas L et al. Double-blind, double-dummy, randomized, placebo-controlled, multicenter trial of budesonide and mesalamine in collagenous colitis. Gastroenterology 2014; 146: 1222-30.
119. Fernandez-Banares F, Salas A, Esteve M et al. Collagenous and lymphocytic colitis. evaluation of clinical and histological features, response to treatment, and long-term follow-up. Am J Gastroenterol 2003; 98: 340-7.
120. Stewart MJ, Seow CH, Storr MA. Prednisolone and budesonide for shortand long-term treatment of microscopic colitis: systematic review and meta-analysis. Clin Gastroenterol Hepatol 2011; 9: 881-90.
121. Miehlke S, Hansen JB, Madisch A et al. Risk factors for symptom relapse in collagenous colitis after withdrawal of short-term budesonide therapy. Inflamm Bowel Dis 2013; 19: 2763-7.
122. Pardi DS, Loftus EV, Tremaine WJ et al. Treatment of refractory microscopic colitis with azathioprine and 6-mercaptopurine. Gastroenterology 2001; 120: 1483-4.
123. Vennamaneni SR, Bonner GF. Use of azathioprine or 6-mercaptopurine for treatment of steroid-dependent lymphocytic and collagenous colitis. Am J Gastroenterol 2001; 96: 2798-9.
124. Riddell J, Hillman L, Chiragakis L, Clarke A. Collagenous colitis: oral low-dose methotrexate for patients with difficult symptoms: Long-term outcomes. J Gastroenterol Hepatol 2007; 22: 1589-93.
125. Kia H, Ting AYS, Dowling D. Letter: oral low-dose methotrexate for collagenous colitis. Aliment Pharmacol Ther 2016; 44: 97.
126. Miehlke S, Madish A, Bethke B et al. Oral budesonide for maintenance treatment of collagenous colitis: a randomized, double-blind, placebo controlled trial. Gastroenterology 2008; 135: 1510-6.
127. Bonderup OK, Hansen JB, Teglbjoerg PS et al. Long-term budesonide treatment of collagenous colitis: a randomised, double-blind, placebocontrolled trial. Gut 2009; 58: 68-72.
128. Munch A, Bohr J, Miehlke S et al. Low-dose budesonide for maintenance of clinical remission in collagenous colitis: a randomised, placebo-controlled, 12-month trial. Gut 2015; 65: 47-56.
129. Pardi DS. After budesonide, what next for collagenous colitis? Gut 2009; 58: 3-4.
130. Munch A, Fernandez-Banares F, Munck LK. Azathioprine and mercaptopurine in the management of patients with chronic, active microscopic colitis. Aliment Pharmacol Ther 2013; 37: 795-8.
131. Munch A, Bohr J, Vigren L et al. Lack of effect of methotrexate in budesonide-refractory collagenous colitis. Clin Exp Gastroenterol 2013; 6: 149-52.
132. Esteve M, Mahadevan U, Sainz E et al. Efficacy of anti-TNF therapies in refractory severe microscopic colitis. J Crohns Colitis 2011; 5: 612-8.
133. Munch A, Ignatova S, Strom M. Adalimumab in budesonide and methotrexate refractory collagenous colitis. Scand J Gastroenterol 2012; 47: 59-63
134. Pola S, Fahmy M, Evans E et al. Successful use of infliximab in the treatment of corticosteroid dependent collagenous colitis. Am J Gastroenterol 2013; 108: 857-8.
135. Williams RA, Gelfand DV. Total proctocolectomy and ileal pouch anal anastomosis to successfully treat a patient with collagenous colitis. Am J Gastroenterol 2000; 95: 2147.
136. Varghese L, Galandiuk S, Tremaine WJ et al. Lymphocytic colitis treated with proctocolectomy and ileal J-pouch anal anastomosis. Dis Colon Rect 2002; 45: 123-6.